Skip to main content
Top
Published in: Journal of Inherited Metabolic Disease 4/2018

Open Access 01-07-2018 | Original Article

Natural history of neurological abnormalities in cerebrotendinous xanthomatosis

Authors: Janice C. Wong, Kailey Walsh, Douglas Hayden, Florian S. Eichler

Published in: Journal of Inherited Metabolic Disease | Issue 4/2018

Login to get access

Abstract

Objectives

Cerebrotendinous xanthomatosis (CTX) is a rare inherited neurodegenerative disorder in bile acid synthesis. The natural history of neurological abnormalities in CTX is not well understood. The object of this study was to determine neurological progression in CTX.

Methods

A literature search on PubMed for “cerebrotendinous xanthomatosis” yielded 91 publications that reported cases of CTX patients. Two independent reviewers abstracted information about the presence and age of onset of neurological abnormalities in published CTX cases. For each neurological abnormality, we estimated the probability of its onset at any given age using cumulative incidence function analysis. We also present our own case series, in which five CTX patients were evaluated.

Results

The literature search yielded 194 CTX cases (ages ranging from newborn to 67 years old). The most common neurological abnormalities were corticospinal tract abnormalities including weakness, hyperreflexia, spasticity, Babinski sign (59.8%), ataxia (58.8%), cognitive decline (46.4%), and gait difficulty (38.1%); 68 (35.0%) had baseline cognitive problems. Cumulative incidence function analysis revealed that ataxia, gait difficulties, and corticospinal tract abnormalities developed throughout life, while cognitive decline tended to develop later in life. Of the less common neurological abnormalities, seizures, psychiatric changes and speech changes developed throughout life, while parkinsonism and sensory changes tended to develop later in life. Our case series corroborated this temporal pattern of neurological abnormalities.

Conclusion

We provide estimates for the neurological progression of CTX, categorizing neurological abnormalities according to time and probability of development. Our approach may be applicable to other rare disorders.
Literature
go back to reference Agrawal NK, Garg S (2012) Cerebrotendinous xanthomatosis: a rare disorder with a rare presentation. BMJ Case Rep. http://dx.doi.org/10.1136/bcr-2012-006202 Agrawal NK, Garg S (2012) Cerebrotendinous xanthomatosis: a rare disorder with a rare presentation. BMJ Case Rep. http://​dx.​doi.​org/​10.​1136/​bcr-2012-006202
go back to reference Androdias G, Vukusic S, Gignoux L et al (2012) Leukodystrophy with a cerebellar cystic aspect and intracranial atherosclerosis: an atypical presentation of cerebrotendinous xanthomatosis. J Neurol 259:364–366CrossRefPubMed Androdias G, Vukusic S, Gignoux L et al (2012) Leukodystrophy with a cerebellar cystic aspect and intracranial atherosclerosis: an atypical presentation of cerebrotendinous xanthomatosis. J Neurol 259:364–366CrossRefPubMed
go back to reference Barkhof F, Verrips A, Wesseling P et al (2000) Cerebrotendinous xanthomatosis: the spectrum of imaging findings and the correlation with neuropathologic findings. Radiology 217:869–876CrossRefPubMed Barkhof F, Verrips A, Wesseling P et al (2000) Cerebrotendinous xanthomatosis: the spectrum of imaging findings and the correlation with neuropathologic findings. Radiology 217:869–876CrossRefPubMed
go back to reference Bartholdi D, Zumsteg D, Verrips A et al (2004) Spinal phenotype of cerebrotendinous xanthomatosis--a pitfall in the diagnosis of multiple sclerosis. J Neurol 251:105–107CrossRefPubMed Bartholdi D, Zumsteg D, Verrips A et al (2004) Spinal phenotype of cerebrotendinous xanthomatosis--a pitfall in the diagnosis of multiple sclerosis. J Neurol 251:105–107CrossRefPubMed
go back to reference Berginer VM, Salen G, Shefer S (1984) Long-term treatment of cerebrotendinous xanthomatosis with chenodeoxycholic acid. N Engl J Med 311:1649–1652CrossRefPubMed Berginer VM, Salen G, Shefer S (1984) Long-term treatment of cerebrotendinous xanthomatosis with chenodeoxycholic acid. N Engl J Med 311:1649–1652CrossRefPubMed
go back to reference Berginer VM, Carmi R, Salen G (1988a) Pregnancy in women with cerebrotendinous xanthomatosis (CTX): high risk condition for fetus and newborn infant? Am J Med Genet 31:11–16CrossRefPubMed Berginer VM, Carmi R, Salen G (1988a) Pregnancy in women with cerebrotendinous xanthomatosis (CTX): high risk condition for fetus and newborn infant? Am J Med Genet 31:11–16CrossRefPubMed
go back to reference Berginer VM, Foster NL, Sadowsky M, Townsend JA 3rd, Siegel GJ, Salen G (1988b) Psychiatric disorders in patients with cerebrotendinous xanthomatosis. Am J Psychiatry 145:354–357CrossRefPubMed Berginer VM, Foster NL, Sadowsky M, Townsend JA 3rd, Siegel GJ, Salen G (1988b) Psychiatric disorders in patients with cerebrotendinous xanthomatosis. Am J Psychiatry 145:354–357CrossRefPubMed
go back to reference Berginer VM, Gross B, Morad K et al (2009) Chronic diarrhea and juvenile cataracts: think cerebrotendinous xanthomatosis and treat. Pediatrics 123:143–147CrossRefPubMed Berginer VM, Gross B, Morad K et al (2009) Chronic diarrhea and juvenile cataracts: think cerebrotendinous xanthomatosis and treat. Pediatrics 123:143–147CrossRefPubMed
go back to reference Bhattacharyya AK, Lin DS, Connor WE (2007) Cholestanol metabolism in patients with cerebrotendinous xanthomatosis: absorption, turnover, and tissue deposition. J Lipid Res 48:185–192CrossRefPubMed Bhattacharyya AK, Lin DS, Connor WE (2007) Cholestanol metabolism in patients with cerebrotendinous xanthomatosis: absorption, turnover, and tissue deposition. J Lipid Res 48:185–192CrossRefPubMed
go back to reference Bhojwani RA, Khot R (2011) Cerebrotendinous xanthomatosis: a rare genetic disorder. BMJ Case Rep. http://dx.doi.org/10.1136/bcr.08.2011.4582 Bhojwani RA, Khot R (2011) Cerebrotendinous xanthomatosis: a rare genetic disorder. BMJ Case Rep. http://​dx.​doi.​org/​10.​1136/​bcr.​08.​2011.​4582
go back to reference Bonnot O, Fraidakis MJ, Lucanto R et al (2010) Cerebrotendinous xanthomatosis presenting with severe externalized disorder: improvement after one year of treatment with chenodeoxycholic acid. CNS Spectr 15:231–236CrossRefPubMed Bonnot O, Fraidakis MJ, Lucanto R et al (2010) Cerebrotendinous xanthomatosis presenting with severe externalized disorder: improvement after one year of treatment with chenodeoxycholic acid. CNS Spectr 15:231–236CrossRefPubMed
go back to reference Bourkiza R, Joyce S, Patel H et al (2010) Cerebrotendinous xanthomatosis (CTX): an association of pulverulent cataracts and pseudo-dominant developmental delay in a family with a splice site mutation in CYP27A1—a case report. Ophthalmic Genet 31:73–76 Bourkiza R, Joyce S, Patel H et al (2010) Cerebrotendinous xanthomatosis (CTX): an association of pulverulent cataracts and pseudo-dominant developmental delay in a family with a splice site mutation in CYP27A1—a case report. Ophthalmic Genet 31:73–76
go back to reference Brodsky JW, Beischer AD, Anat D et al (2006) Cerebrotendinous xanthomatosis: a rare cause of bilateral Achilles tendon swelling and ataxia. A case report. J Bone Joint Surg Am 88:1340–1344PubMed Brodsky JW, Beischer AD, Anat D et al (2006) Cerebrotendinous xanthomatosis: a rare cause of bilateral Achilles tendon swelling and ataxia. A case report. J Bone Joint Surg Am 88:1340–1344PubMed
go back to reference Burnett JR, Moses EA, Croft KD et al (2001) Clinical and biochemical features, molecular diagnosis and long-term management of a case of cerebrotendinous xanthomatosis. Clin Chim Acta 306:63–69CrossRefPubMed Burnett JR, Moses EA, Croft KD et al (2001) Clinical and biochemical features, molecular diagnosis and long-term management of a case of cerebrotendinous xanthomatosis. Clin Chim Acta 306:63–69CrossRefPubMed
go back to reference Canelas HM, Quintao EC, Scaff M, Vasconcelos KS, Brotto MW (1983) Cerebrotendinous xanthomatosis: clinical and laboratory study of 2 cases. Acta Neurol Scand 67:305–311CrossRefPubMed Canelas HM, Quintao EC, Scaff M, Vasconcelos KS, Brotto MW (1983) Cerebrotendinous xanthomatosis: clinical and laboratory study of 2 cases. Acta Neurol Scand 67:305–311CrossRefPubMed
go back to reference Cerqueira AC, Nardi AE, Bezerra JM (2010) Cerebrotendinous xanthomatosis: a treatable hereditary neuro-metabolic disease. Clinics (Sao Paulo) 65:1217–1218CrossRef Cerqueira AC, Nardi AE, Bezerra JM (2010) Cerebrotendinous xanthomatosis: a treatable hereditary neuro-metabolic disease. Clinics (Sao Paulo) 65:1217–1218CrossRef
go back to reference Chang CC, Lui CC, Wang JJ et al (2010) Multi-parametric neuroimaging evaluation of cerebrotendinous xanthomatosis and its correlation with neuropsychological presentations. BMC Neurol 10:59CrossRefPubMedPubMedCentral Chang CC, Lui CC, Wang JJ et al (2010) Multi-parametric neuroimaging evaluation of cerebrotendinous xanthomatosis and its correlation with neuropsychological presentations. BMC Neurol 10:59CrossRefPubMedPubMedCentral
go back to reference Chang WN, Kuriyama M, Lui CC, Jeng SF, Chen WJ, Chee EC (1992) Cerebrotendinous xanthomatosis in three siblings from a Taiwanese family. J Formos Med Assoc 91:1190–1194PubMed Chang WN, Kuriyama M, Lui CC, Jeng SF, Chen WJ, Chee EC (1992) Cerebrotendinous xanthomatosis in three siblings from a Taiwanese family. J Formos Med Assoc 91:1190–1194PubMed
go back to reference Chen W, Kubota S, Teramoto T et al (1998) Genetic analysis enables definite and rapid diagnosis of cerebrotendinous xanthomatosis. Neurology 51:865–867CrossRefPubMed Chen W, Kubota S, Teramoto T et al (1998) Genetic analysis enables definite and rapid diagnosis of cerebrotendinous xanthomatosis. Neurology 51:865–867CrossRefPubMed
go back to reference Chen SF, Tsai NW, Chang CC et al (2011a) Neuromuscular abnormality and autonomic dysfunction in patients with cerebrotendinous xanthomatosis. BMC Neurol 11:63CrossRefPubMedPubMedCentral Chen SF, Tsai NW, Chang CC et al (2011a) Neuromuscular abnormality and autonomic dysfunction in patients with cerebrotendinous xanthomatosis. BMC Neurol 11:63CrossRefPubMedPubMedCentral
go back to reference Chen WC, Wu KC, Hu CH, Chern TC, Jou IM (2011b) A compound heterozygous mutation of CYP27A1 gene in a Taiwanese patient with cerebrotendinous xanthomatosis. J Orthop Sci 16:825–827CrossRefPubMed Chen WC, Wu KC, Hu CH, Chern TC, Jou IM (2011b) A compound heterozygous mutation of CYP27A1 gene in a Taiwanese patient with cerebrotendinous xanthomatosis. J Orthop Sci 16:825–827CrossRefPubMed
go back to reference Chen Q, Liu W, Jiang B, Yu R, Li X, Li H (2012) Fluoxetine-responsive depression in a Chinese cerebrotendinous xanthomatosis. Gen Hosp Psychiatry 34(578):e571–e574 Chen Q, Liu W, Jiang B, Yu R, Li X, Li H (2012) Fluoxetine-responsive depression in a Chinese cerebrotendinous xanthomatosis. Gen Hosp Psychiatry 34(578):e571–e574
go back to reference Clemen CS, Spottke EA, Lutjohann D et al (2005) Cerebrotendinous xanthomatosis: a treatable ataxia. Neurology 64:1476CrossRefPubMed Clemen CS, Spottke EA, Lutjohann D et al (2005) Cerebrotendinous xanthomatosis: a treatable ataxia. Neurology 64:1476CrossRefPubMed
go back to reference Degos B, Nadjar Y, Amador Mdel M et al (2016) Natural history of cerebrotendinous xanthomatosis: a paediatric disease diagnosed in adulthood. Orphanet J Rare Dis 11:41CrossRefPubMedPubMedCentral Degos B, Nadjar Y, Amador Mdel M et al (2016) Natural history of cerebrotendinous xanthomatosis: a paediatric disease diagnosed in adulthood. Orphanet J Rare Dis 11:41CrossRefPubMedPubMedCentral
go back to reference Dormans TP, Verrips A, Bulten J, Cox N (1997) Pulmonary lymphangioleiomyomatosis and cerebrotendinous xanthomatosis: is there a link? Chest 112:273–274CrossRefPubMed Dormans TP, Verrips A, Bulten J, Cox N (1997) Pulmonary lymphangioleiomyomatosis and cerebrotendinous xanthomatosis: is there a link? Chest 112:273–274CrossRefPubMed
go back to reference Dotti MT, Federico A, Signorini E et al (1994) Cerebrotendinous xanthomatosis (van Bogaert-Scherer-Epstein disease): CT and MR findings. AJNR Am J Neuroradiol 15:1721–1726PubMed Dotti MT, Federico A, Signorini E et al (1994) Cerebrotendinous xanthomatosis (van Bogaert-Scherer-Epstein disease): CT and MR findings. AJNR Am J Neuroradiol 15:1721–1726PubMed
go back to reference Dotti MT, Manneschi L, Federico A (1995) Mitochondrial enzyme deficiency in cerebrotendinous xanthomatosis. J Neurol Sci 129:106–108CrossRefPubMed Dotti MT, Manneschi L, Federico A (1995) Mitochondrial enzyme deficiency in cerebrotendinous xanthomatosis. J Neurol Sci 129:106–108CrossRefPubMed
go back to reference Farpour H, Mahloudji M (1975) Familial cerebrotendinous xanthomatosis. Report of a new family and review of the literature. Arch Neurol 32:223–225CrossRefPubMed Farpour H, Mahloudji M (1975) Familial cerebrotendinous xanthomatosis. Report of a new family and review of the literature. Arch Neurol 32:223–225CrossRefPubMed
go back to reference Gaikwad SB, Garg A, Mishra NK, Gupta V, Srivastava A, Sarkar C (2003) Cerebrotendinous xanthomatosis: neuroimaging findings in two siblings from an Indian family. Neurol India 51:401–403PubMed Gaikwad SB, Garg A, Mishra NK, Gupta V, Srivastava A, Sarkar C (2003) Cerebrotendinous xanthomatosis: neuroimaging findings in two siblings from an Indian family. Neurol India 51:401–403PubMed
go back to reference Gallus GN, Dotti MT, Mignarri A et al (2010) Four novel CYP27A1 mutations in seven Italian patients with CTX. Eur J Neurol 17:1259–1262CrossRefPubMed Gallus GN, Dotti MT, Mignarri A et al (2010) Four novel CYP27A1 mutations in seven Italian patients with CTX. Eur J Neurol 17:1259–1262CrossRefPubMed
go back to reference Geraldes R, Santos-Bento M, de Carvalho M (2007) Cerebrotendinous xanthomatosis: no involvement of the autonomic nervous system in a case with severe neuropathy. Neurophysiol Clin 37:47–49CrossRefPubMed Geraldes R, Santos-Bento M, de Carvalho M (2007) Cerebrotendinous xanthomatosis: no involvement of the autonomic nervous system in a case with severe neuropathy. Neurophysiol Clin 37:47–49CrossRefPubMed
go back to reference Gonzalez-Cuyar LF, Hunter B, Harris PL, Perry G, Smith MA, Castellani RJ (2007) Cerebrotendinous xanthomatosis: case report with evidence of oxidative stress. Redox Rep 12:119–124CrossRefPubMed Gonzalez-Cuyar LF, Hunter B, Harris PL, Perry G, Smith MA, Castellani RJ (2007) Cerebrotendinous xanthomatosis: case report with evidence of oxidative stress. Redox Rep 12:119–124CrossRefPubMed
go back to reference Habaragamuwa BW, Bajekal R (2010) Cerebrotendinous xanthomatosis and anaesthesia. Br J Anaesth 105:237–238CrossRefPubMed Habaragamuwa BW, Bajekal R (2010) Cerebrotendinous xanthomatosis and anaesthesia. Br J Anaesth 105:237–238CrossRefPubMed
go back to reference Hansson M, Olin M, Floren CH et al (2007) Unique patient with cerebrotendinous xanthomatosis. Evidence for presence of a defect in a gene that is not identical to sterol 27-hydroxylase. J Intern Med 261:504–510CrossRefPubMed Hansson M, Olin M, Floren CH et al (2007) Unique patient with cerebrotendinous xanthomatosis. Evidence for presence of a defect in a gene that is not identical to sterol 27-hydroxylase. J Intern Med 261:504–510CrossRefPubMed
go back to reference Hokezu Y, Kuriyama M, Kubota R, Nakagawa M, Fujiyama J, Osame M (1992) Cerebrotendinous xanthomatosis: cranial CT and MRI studies in eight patients. Neuroradiology 34:308–312CrossRefPubMed Hokezu Y, Kuriyama M, Kubota R, Nakagawa M, Fujiyama J, Osame M (1992) Cerebrotendinous xanthomatosis: cranial CT and MRI studies in eight patients. Neuroradiology 34:308–312CrossRefPubMed
go back to reference Huang L, Miao XD, Yang DS, Tao HM (2011) Bilateral Achilles tendon enlargement. Orthopedics 34:e960–e964PubMed Huang L, Miao XD, Yang DS, Tao HM (2011) Bilateral Achilles tendon enlargement. Orthopedics 34:e960–e964PubMed
go back to reference Huijgen R, Stork AD, Defesche JC et al (2012) Extreme xanthomatosis in patients with both familial hypercholesterolemia and cerebrotendinous xanthomatosis. Clin Genet 81:24–28CrossRefPubMed Huijgen R, Stork AD, Defesche JC et al (2012) Extreme xanthomatosis in patients with both familial hypercholesterolemia and cerebrotendinous xanthomatosis. Clin Genet 81:24–28CrossRefPubMed
go back to reference Ito S, Kuwabara S, Sakakibara R et al (2003) Combined treatment with LDL-apheresis, chenodeoxycholic acid and HMG-CoA reductase inhibitor for cerebrotendinous xanthomatosis. J Neurol Sci 216:179–182CrossRefPubMed Ito S, Kuwabara S, Sakakibara R et al (2003) Combined treatment with LDL-apheresis, chenodeoxycholic acid and HMG-CoA reductase inhibitor for cerebrotendinous xanthomatosis. J Neurol Sci 216:179–182CrossRefPubMed
go back to reference Jain RS, Sannegowda RB, Agrawal A, Hemrajani D, Jain R, Mathur T (2013) ‘Hot cross bun’ sign in a case of cerebrotendinous xanthomatosis: a rare neuroimaging observation. BMJ Case Rep. http://dx.doi.org/10.1136/bcr-2012-006641 Jain RS, Sannegowda RB, Agrawal A, Hemrajani D, Jain R, Mathur T (2013) ‘Hot cross bun’ sign in a case of cerebrotendinous xanthomatosis: a rare neuroimaging observation. BMJ Case Rep. http://​dx.​doi.​org/​10.​1136/​bcr-2012-006641
go back to reference Kamate M, Chetal V, Hattiholi V (2010) Cerebrotendinous xanthomatosis. Indian J Pediatr 77:697–698CrossRefPubMed Kamate M, Chetal V, Hattiholi V (2010) Cerebrotendinous xanthomatosis. Indian J Pediatr 77:697–698CrossRefPubMed
go back to reference Kapas I, Katko M, Harangi M et al (2014) Cerebrotendinous xanthomatosis with the c.379C>T (p.R127W) mutation in the CYP27A1 gene associated with premature age-associated limbic tauopathy. Neuropathol Appl Neurobiol 40:345–350CrossRefPubMed Kapas I, Katko M, Harangi M et al (2014) Cerebrotendinous xanthomatosis with the c.379C>T (p.R127W) mutation in the CYP27A1 gene associated with premature age-associated limbic tauopathy. Neuropathol Appl Neurobiol 40:345–350CrossRefPubMed
go back to reference Kato H, Koyabu S, Aoki S et al (2003) An autopsy case of gallbladder cancer developing in a Japanese man with cerebrotendinous xanthomatosis: genetic analysis of the sterol 27-hydroxylase and p53 genes. Pathology 35:141–144PubMed Kato H, Koyabu S, Aoki S et al (2003) An autopsy case of gallbladder cancer developing in a Japanese man with cerebrotendinous xanthomatosis: genetic analysis of the sterol 27-hydroxylase and p53 genes. Pathology 35:141–144PubMed
go back to reference Katz DA, Scheinberg L, Horoupian DS, Salen G (1985) Peripheral neuropathy in cerebrotendinous xanthomatosis. Arch Neurol 42:1008–1010CrossRefPubMed Katz DA, Scheinberg L, Horoupian DS, Salen G (1985) Peripheral neuropathy in cerebrotendinous xanthomatosis. Arch Neurol 42:1008–1010CrossRefPubMed
go back to reference Kauffman MA, Gonzalez-Moron D, Consalvo D, Kochen S (2012) Cerebrotendinous xanthomatosis revealed in drug-resistant epilepsy diagnostic workup. Am J Med Sci 343:332–333CrossRefPubMed Kauffman MA, Gonzalez-Moron D, Consalvo D, Kochen S (2012) Cerebrotendinous xanthomatosis revealed in drug-resistant epilepsy diagnostic workup. Am J Med Sci 343:332–333CrossRefPubMed
go back to reference Kawabata M, Kuriyama M, Mori S, Sakashita I, Osame M (1998) Pulmonary manifestations in cerebrotendinous xanthomatosis. Intern Med 37:922–926CrossRefPubMed Kawabata M, Kuriyama M, Mori S, Sakashita I, Osame M (1998) Pulmonary manifestations in cerebrotendinous xanthomatosis. Intern Med 37:922–926CrossRefPubMed
go back to reference Khan AO, Aldahmesh MA, Mohamed JY, Alkuraya FS (2013) Juvenile cataract morphology in 3 siblings not yet diagnosed with cerebrotendinous xanthomatosis. Ophthalmology 120:956–960CrossRefPubMed Khan AO, Aldahmesh MA, Mohamed JY, Alkuraya FS (2013) Juvenile cataract morphology in 3 siblings not yet diagnosed with cerebrotendinous xanthomatosis. Ophthalmology 120:956–960CrossRefPubMed
go back to reference Kottahachchi DC, Balasooriya BL, Panangala L, Ranawaka UK (2012) Two siblings with cerebrotendinous xanthomatosis. Ceylon Med J 57:128–129CrossRefPubMed Kottahachchi DC, Balasooriya BL, Panangala L, Ranawaka UK (2012) Two siblings with cerebrotendinous xanthomatosis. Ceylon Med J 57:128–129CrossRefPubMed
go back to reference Koyama S, Kawanami T, Tanji H et al (2012) A case of cerebrotendinous xanthomatosis presenting with epilepsy as an initial symptom with a novel V413D mutation in the CYP27A1 gene. Clin Neurol Neurosurg 114:1021–1023CrossRefPubMed Koyama S, Kawanami T, Tanji H et al (2012) A case of cerebrotendinous xanthomatosis presenting with epilepsy as an initial symptom with a novel V413D mutation in the CYP27A1 gene. Clin Neurol Neurosurg 114:1021–1023CrossRefPubMed
go back to reference Kuwabara K, Hitoshi S, Nukina N et al (1996) PET analysis of a case of cerebrotendinous xanthomatosis presenting hemiparkinsonism. J Neurol Sci 138:145–149CrossRefPubMed Kuwabara K, Hitoshi S, Nukina N et al (1996) PET analysis of a case of cerebrotendinous xanthomatosis presenting hemiparkinsonism. J Neurol Sci 138:145–149CrossRefPubMed
go back to reference Lange MC, Zetola VF, Teive HA et al (2004) Cerebrotendinous xanthomatosis: report of two Brazilian brothers. Arq Neuropsiquiatr 62:1085–1089CrossRefPubMed Lange MC, Zetola VF, Teive HA et al (2004) Cerebrotendinous xanthomatosis: report of two Brazilian brothers. Arq Neuropsiquiatr 62:1085–1089CrossRefPubMed
go back to reference Lee Y, Lin PY, Chiu NM, Chang WN, Wen JK (2002) Cerebrotendinous xanthomatosis with psychiatric disorders: report of three siblings and literature review. Chang Gung Med J 25:334–340PubMed Lee Y, Lin PY, Chiu NM, Chang WN, Wen JK (2002) Cerebrotendinous xanthomatosis with psychiatric disorders: report of three siblings and literature review. Chang Gung Med J 25:334–340PubMed
go back to reference Lorincz MT, Rainier S, Thomas D, Fink JK (2005) Cerebrotendinous xanthomatosis: possible higher prevalence than previously recognized. Arch Neurol 62:1459–1463CrossRefPubMed Lorincz MT, Rainier S, Thomas D, Fink JK (2005) Cerebrotendinous xanthomatosis: possible higher prevalence than previously recognized. Arch Neurol 62:1459–1463CrossRefPubMed
go back to reference Luyckx E, Eyskens F, Simons A, Beckx K, Van West D, Dhar M (2014) Long-term follow-up on the effect of combined therapy of bile acids and statins in the treatment of cerebrotendinous xanthomatosis: a case report. Clin Neurol Neurosurg 118:9–11CrossRefPubMed Luyckx E, Eyskens F, Simons A, Beckx K, Van West D, Dhar M (2014) Long-term follow-up on the effect of combined therapy of bile acids and statins in the treatment of cerebrotendinous xanthomatosis: a case report. Clin Neurol Neurosurg 118:9–11CrossRefPubMed
go back to reference Mandrile G, Gallus GN, Mura G et al (2014) Cerebrotendinous xanthomatosis: recurrence of the CYP27A1 mutation p.Arg479Cys in Sardinia. Neurol Sci 35:1303–1305PubMed Mandrile G, Gallus GN, Mura G et al (2014) Cerebrotendinous xanthomatosis: recurrence of the CYP27A1 mutation p.Arg479Cys in Sardinia. Neurol Sci 35:1303–1305PubMed
go back to reference Matysik S, Orso E, Black A, Ahrens N, Schmitz G (2011) Monitoring of 7alpha-hydroxy-4-cholesten-3-one during therapy of cerebrotendinous xanthomatosis: a case report. Chem Phys Lipids 164:530–534CrossRefPubMed Matysik S, Orso E, Black A, Ahrens N, Schmitz G (2011) Monitoring of 7alpha-hydroxy-4-cholesten-3-one during therapy of cerebrotendinous xanthomatosis: a case report. Chem Phys Lipids 164:530–534CrossRefPubMed
go back to reference McKinnon JH, Bosch EP (2012) Clinical reasoning: a case of treatable spastic paraparesis. Neurology 79:e50–e53CrossRefPubMed McKinnon JH, Bosch EP (2012) Clinical reasoning: a case of treatable spastic paraparesis. Neurology 79:e50–e53CrossRefPubMed
go back to reference Meiner V, Meiner Z, Reshef A, Bjorkhem I, Leitersdorf E (1994) Cerebrotendinous xanthomatosis: molecular diagnosis enables presymptomatic detection of a treatable disease. Neurology 44:288–290CrossRefPubMed Meiner V, Meiner Z, Reshef A, Bjorkhem I, Leitersdorf E (1994) Cerebrotendinous xanthomatosis: molecular diagnosis enables presymptomatic detection of a treatable disease. Neurology 44:288–290CrossRefPubMed
go back to reference Menkes JH, Schimschock JR, Swanson PD (1968) Cerebrotendinous xanthomatosis. The storage of cholestanol within the nervous system. Arch Neurol 19:47–53CrossRefPubMed Menkes JH, Schimschock JR, Swanson PD (1968) Cerebrotendinous xanthomatosis. The storage of cholestanol within the nervous system. Arch Neurol 19:47–53CrossRefPubMed
go back to reference Mignarri A, Dotti MT, Del Puppo M et al (2012a) Cerebrotendinous xanthomatosis with progressive cerebellar vacuolation : six-year MRI follow-up. Neuroradiology 54:649–651CrossRefPubMed Mignarri A, Dotti MT, Del Puppo M et al (2012a) Cerebrotendinous xanthomatosis with progressive cerebellar vacuolation : six-year MRI follow-up. Neuroradiology 54:649–651CrossRefPubMed
go back to reference Mignarri A, Falcini M, Vella A et al (2012b) Parkinsonism as neurological presentation of late-onset cerebrotendinous xanthomatosis. Parkinsonism Relat Disord 18:99–101CrossRefPubMed Mignarri A, Falcini M, Vella A et al (2012b) Parkinsonism as neurological presentation of late-onset cerebrotendinous xanthomatosis. Parkinsonism Relat Disord 18:99–101CrossRefPubMed
go back to reference Mignarri A, Gallus GN, Dotti MT, Federico A (2014) A suspicion index for early diagnosis and treatment of cerebrotendinous xanthomatosis. J Inherit Metab Dis 37:421–429CrossRefPubMed Mignarri A, Gallus GN, Dotti MT, Federico A (2014) A suspicion index for early diagnosis and treatment of cerebrotendinous xanthomatosis. J Inherit Metab Dis 37:421–429CrossRefPubMed
go back to reference Moghadasian MH, Salen G, Frohlich JJ, Scudamore CH (2002) Cerebrotendinous xanthomatosis: a rare disease with diverse manifestations. Arch Neurol 59:527–529CrossRefPubMed Moghadasian MH, Salen G, Frohlich JJ, Scudamore CH (2002) Cerebrotendinous xanthomatosis: a rare disease with diverse manifestations. Arch Neurol 59:527–529CrossRefPubMed
go back to reference Mondelli M, Rossi A, Scarpini C, Dotti MT, Federico A (1992) Evoked potentials in cerebrotendinous xanthomatosis and effect induced by chenodeoxycholic acid. Arch Neurol 49:469–475CrossRefPubMed Mondelli M, Rossi A, Scarpini C, Dotti MT, Federico A (1992) Evoked potentials in cerebrotendinous xanthomatosis and effect induced by chenodeoxycholic acid. Arch Neurol 49:469–475CrossRefPubMed
go back to reference Monson DM, DeBarber AE, Bock CJ et al (2011) Cerebrotendinous xanthomatosis: a treatable disease with juvenile cataracts as a presenting sign. Arch Ophthalmol 129:1087–1088CrossRefPubMedPubMedCentral Monson DM, DeBarber AE, Bock CJ et al (2011) Cerebrotendinous xanthomatosis: a treatable disease with juvenile cataracts as a presenting sign. Arch Ophthalmol 129:1087–1088CrossRefPubMedPubMedCentral
go back to reference Nakashima N, Sakai Y, Sakai H et al (1994) A point mutation in the bile acid biosynthetic enzyme sterol 27-hydroxylase in a family with cerebrotendinous xanthomatosis. J Lipid Res 35:663–668PubMed Nakashima N, Sakai Y, Sakai H et al (1994) A point mutation in the bile acid biosynthetic enzyme sterol 27-hydroxylase in a family with cerebrotendinous xanthomatosis. J Lipid Res 35:663–668PubMed
go back to reference Nie S, Chen G, Cao X, Zhang Y (2014) Cerebrotendinous xanthomatosis: a comprehensive review of pathogenesis, clinical manifestations, diagnosis, and management. Orphanet J Rare Dis 9:179CrossRefPubMedPubMedCentral Nie S, Chen G, Cao X, Zhang Y (2014) Cerebrotendinous xanthomatosis: a comprehensive review of pathogenesis, clinical manifestations, diagnosis, and management. Orphanet J Rare Dis 9:179CrossRefPubMedPubMedCentral
go back to reference Nozue T, Higashikata T, Inazu A et al (2010) Identification of a novel missense mutation in the sterol 27-hydroxylase gene in two Japanese patients with cerebrotendinous xanthomatosis. Intern Med 49:1127–1131CrossRefPubMed Nozue T, Higashikata T, Inazu A et al (2010) Identification of a novel missense mutation in the sterol 27-hydroxylase gene in two Japanese patients with cerebrotendinous xanthomatosis. Intern Med 49:1127–1131CrossRefPubMed
go back to reference Ohno T, Kobayashi S, Hayashi M, Sakurai M, Kanazawa I (2001) Diphenylpyraline-responsive parkinsonism in cerebrotendinous xanthomatosis: long-term follow up of three patients. J Neurol Sci 182:95–97CrossRefPubMed Ohno T, Kobayashi S, Hayashi M, Sakurai M, Kanazawa I (2001) Diphenylpyraline-responsive parkinsonism in cerebrotendinous xanthomatosis: long-term follow up of three patients. J Neurol Sci 182:95–97CrossRefPubMed
go back to reference Okuma H, Kitagawa Y, Tokuoka K, Takagi S (2007) Cerebrotendinous xanthomatosis with cerebellar ataxia as the chief symptom. Intern Med 46:1259–1261CrossRefPubMed Okuma H, Kitagawa Y, Tokuoka K, Takagi S (2007) Cerebrotendinous xanthomatosis with cerebellar ataxia as the chief symptom. Intern Med 46:1259–1261CrossRefPubMed
go back to reference Pedroso JL, Pinto WB, Souza PV et al (2012) Early-onset epilepsy as the main neurological manifestation of cerebrotendinous xanthomatosis. Epilepsy Behav 24:380–381CrossRefPubMed Pedroso JL, Pinto WB, Souza PV et al (2012) Early-onset epilepsy as the main neurological manifestation of cerebrotendinous xanthomatosis. Epilepsy Behav 24:380–381CrossRefPubMed
go back to reference Philippart M, Van Bogaert L (1969) Cholestanolosis (cerebrotendinous xanthomatosis). A follow-up study on the original family. Arch Neurol 21:603–610CrossRefPubMed Philippart M, Van Bogaert L (1969) Cholestanolosis (cerebrotendinous xanthomatosis). A follow-up study on the original family. Arch Neurol 21:603–610CrossRefPubMed
go back to reference Pilo-de-la-Fuente B, Jimenez-Escrig A, Lorenzo JR et al (2011) Cerebrotendinous xanthomatosis in Spain: clinical, prognostic, and genetic survey. Eur J Neurol 18:1203–1211CrossRefPubMed Pilo-de-la-Fuente B, Jimenez-Escrig A, Lorenzo JR et al (2011) Cerebrotendinous xanthomatosis in Spain: clinical, prognostic, and genetic survey. Eur J Neurol 18:1203–1211CrossRefPubMed
go back to reference Pilo de la Fuente B, Ruiz I, Lopez de Munain A, Jimenez-Escrig A (2008) Cerebrotendinous xanthomatosis: neuropathological findings. J Neurol 255:839–842CrossRefPubMed Pilo de la Fuente B, Ruiz I, Lopez de Munain A, Jimenez-Escrig A (2008) Cerebrotendinous xanthomatosis: neuropathological findings. J Neurol 255:839–842CrossRefPubMed
go back to reference Posada IJ, Ramos A (2011) Botulinum toxin-responsive oromandibular dystonia in cerebrotendinous xanthomatosis. Parkinsonism Relat Disord 17:570–572CrossRefPubMed Posada IJ, Ramos A (2011) Botulinum toxin-responsive oromandibular dystonia in cerebrotendinous xanthomatosis. Parkinsonism Relat Disord 17:570–572CrossRefPubMed
go back to reference Price Evans DA, Salah KA, Mobrad MA, Mitchell WD, Olin M, Eggertsen G (2007) Cerebrotendinous xanthomatosis in a Saudi Arabian family-genotyping and long-term follow-up. Saudi Med J 28:1113–1118PubMed Price Evans DA, Salah KA, Mobrad MA, Mitchell WD, Olin M, Eggertsen G (2007) Cerebrotendinous xanthomatosis in a Saudi Arabian family-genotyping and long-term follow-up. Saudi Med J 28:1113–1118PubMed
go back to reference Pudhiavan A, Agrawal A, Chaudhari S, Shukla A (2013) Cerebrotendinous xanthomatosis--the spectrum of imaging findings. J Radiol Case Rep 7:1–9PubMedPubMedCentral Pudhiavan A, Agrawal A, Chaudhari S, Shukla A (2013) Cerebrotendinous xanthomatosis--the spectrum of imaging findings. J Radiol Case Rep 7:1–9PubMedPubMedCentral
go back to reference Putter H, Fiocco M, Geskus RB (2007) Tutorial in biostatistics: competing risks and multi-state models. Stat Med 26:2389–2430CrossRefPubMed Putter H, Fiocco M, Geskus RB (2007) Tutorial in biostatistics: competing risks and multi-state models. Stat Med 26:2389–2430CrossRefPubMed
go back to reference Rafiq M, Sharrack N, Shaw PJ, Hadjivassiliou M (2011) A neurological rarity not to be missed: cerebrotendinous xanthomatosis. Pract Neurol 11:296–300CrossRefPubMed Rafiq M, Sharrack N, Shaw PJ, Hadjivassiliou M (2011) A neurological rarity not to be missed: cerebrotendinous xanthomatosis. Pract Neurol 11:296–300CrossRefPubMed
go back to reference Reichwaldt I, Zustin J, Wenke K, Ridderbusch I (2010) Differential diagnosis of tendon tumors: xanthomas caused by hyperlipidemia in children. J Pediatr Surg 45:e9–12CrossRefPubMed Reichwaldt I, Zustin J, Wenke K, Ridderbusch I (2010) Differential diagnosis of tendon tumors: xanthomas caused by hyperlipidemia in children. J Pediatr Surg 45:e9–12CrossRefPubMed
go back to reference Rystedt E, Olin M, Seyama Y et al (2002) Cerebrotendinous xanthomatosis: molecular characterization of two Scandinavian sisters. J Intern Med 252:259–264CrossRefPubMed Rystedt E, Olin M, Seyama Y et al (2002) Cerebrotendinous xanthomatosis: molecular characterization of two Scandinavian sisters. J Intern Med 252:259–264CrossRefPubMed
go back to reference Sandeep P, Jayakrishnan C, Sadanan S, Sreekumar S, Thulasidharan NK (2009) Cerebrotendinous xanthomatosis: a treatable neurodegenerative disease. J Assoc Physicians India 57:716–717PubMed Sandeep P, Jayakrishnan C, Sadanan S, Sreekumar S, Thulasidharan NK (2009) Cerebrotendinous xanthomatosis: a treatable neurodegenerative disease. J Assoc Physicians India 57:716–717PubMed
go back to reference Schimschock JR, Alvord EC Jr, Swanson PD (1968) Cerebrotendinous xanthomatosis. Clinical and pathological studies. Arch Neurol 18:688–698CrossRefPubMed Schimschock JR, Alvord EC Jr, Swanson PD (1968) Cerebrotendinous xanthomatosis. Clinical and pathological studies. Arch Neurol 18:688–698CrossRefPubMed
go back to reference Schneider H, Lingesleben A, Vogel HP, Garuti R, Calandra S (2010) A novel mutation in the sterol 27-hydroxylase gene of a woman with autosomal recessive cerebrotendinous xanthomatosis. Orphanet J Rare Dis 5:27CrossRefPubMedPubMedCentral Schneider H, Lingesleben A, Vogel HP, Garuti R, Calandra S (2010) A novel mutation in the sterol 27-hydroxylase gene of a woman with autosomal recessive cerebrotendinous xanthomatosis. Orphanet J Rare Dis 5:27CrossRefPubMedPubMedCentral
go back to reference Schreiner A, Hopen G, Skrede S (1975) Cerebrotendinous xanthomatosis (cholestanolosis). Investigations on two sisters and their family. Acta Neurol Scand 51:405–416CrossRefPubMed Schreiner A, Hopen G, Skrede S (1975) Cerebrotendinous xanthomatosis (cholestanolosis). Investigations on two sisters and their family. Acta Neurol Scand 51:405–416CrossRefPubMed
go back to reference Seidel S, Kasprian G, Prayer D, Krssak M, Sycha T, Auff E (2011) Visualisation of treatment response in a case of cerebrotendinous xanthomatosis. J Neurol Neurosurg Psychiatry 82:703–704CrossRefPubMed Seidel S, Kasprian G, Prayer D, Krssak M, Sycha T, Auff E (2011) Visualisation of treatment response in a case of cerebrotendinous xanthomatosis. J Neurol Neurosurg Psychiatry 82:703–704CrossRefPubMed
go back to reference Sekijima Y, Koyama S, Yoshinaga T, Koinuma M, Inaba Y (2018) Nationwide survey on cerebrotendinous xanthomatosis in Japan. J Hum Genet. http://dx.doi.org/10.1038/s10038-017-0389-4 Sekijima Y, Koyama S, Yoshinaga T, Koinuma M, Inaba Y (2018) Nationwide survey on cerebrotendinous xanthomatosis in Japan. J Hum Genet. http://​dx.​doi.​org/​10.​1038/​s10038-017-0389-4
go back to reference Siman-Tov T, Meiner V, Gadoth N (2006) Could steroids mask the diagnosis of cerebrotendinous xanthomatosis? J Neurol Sci 243:83–86CrossRefPubMed Siman-Tov T, Meiner V, Gadoth N (2006) Could steroids mask the diagnosis of cerebrotendinous xanthomatosis? J Neurol Sci 243:83–86CrossRefPubMed
go back to reference Smithard A, Lamyman MJ, McCarthy CL, Gibbons CL, Cooke PJ, Athanasou N (2007) Cerebrotendinous xanthomatosis presenting with bilateral Achilles tendon xanthomata. Skelet Radiol 36:171–175CrossRef Smithard A, Lamyman MJ, McCarthy CL, Gibbons CL, Cooke PJ, Athanasou N (2007) Cerebrotendinous xanthomatosis presenting with bilateral Achilles tendon xanthomata. Skelet Radiol 36:171–175CrossRef
go back to reference Soffer D, Benharroch D, Berginer V (1995) The neuropathology of cerebrotendinous xanthomatosis revisited: a case report and review of the literature. Acta Neuropathol 90:213–220CrossRefPubMed Soffer D, Benharroch D, Berginer V (1995) The neuropathology of cerebrotendinous xanthomatosis revisited: a case report and review of the literature. Acta Neuropathol 90:213–220CrossRefPubMed
go back to reference Stahl WL, Sumi SM, Swanson PD (1971) Subcellular distribution of cerebral cholestanol in cerebrotendinous xanthomatosis. J Neurochem 18:403–413CrossRefPubMed Stahl WL, Sumi SM, Swanson PD (1971) Subcellular distribution of cerebral cholestanol in cerebrotendinous xanthomatosis. J Neurochem 18:403–413CrossRefPubMed
go back to reference Su CS, Chang WN, Huang SH et al (2010) Cerebrotendinous xanthomatosis patients with and without parkinsonism: clinical characteristics and neuroimaging findings. Mov Disord 25:452–458CrossRefPubMed Su CS, Chang WN, Huang SH et al (2010) Cerebrotendinous xanthomatosis patients with and without parkinsonism: clinical characteristics and neuroimaging findings. Mov Disord 25:452–458CrossRefPubMed
go back to reference Szlago M, Gallus GN, Schenone A et al (2008) The first cerebrotendinous xanthomatosis family from Argentina: a new mutation in CYP27A1 gene. Neurology 70:402–404CrossRefPubMed Szlago M, Gallus GN, Schenone A et al (2008) The first cerebrotendinous xanthomatosis family from Argentina: a new mutation in CYP27A1 gene. Neurology 70:402–404CrossRefPubMed
go back to reference Uygunoglu U, Gunduz A, Menku SF et al (2014) Cerebrotendinous xanthomatosis: the effectiveness of high-dose piracetam for the treatment of cerebellar and sensorial ataxia. Cerebellum 13:787–790CrossRefPubMed Uygunoglu U, Gunduz A, Menku SF et al (2014) Cerebrotendinous xanthomatosis: the effectiveness of high-dose piracetam for the treatment of cerebellar and sensorial ataxia. Cerebellum 13:787–790CrossRefPubMed
go back to reference Valdivielso P, Calandra S, Duran JC, Garuti R, Herrera E, Gonzalez P (2004) Coronary heart disease in a patient with cerebrotendinous xanthomatosis. J Intern Med 255:680–683CrossRefPubMed Valdivielso P, Calandra S, Duran JC, Garuti R, Herrera E, Gonzalez P (2004) Coronary heart disease in a patient with cerebrotendinous xanthomatosis. J Intern Med 255:680–683CrossRefPubMed
go back to reference Van Bogaert L, Scherer HJ, Epstein E (1937) Une forme cerebrale de la cholesterinose generalisee. Masson & Cie, Paris Van Bogaert L, Scherer HJ, Epstein E (1937) Une forme cerebrale de la cholesterinose generalisee. Masson & Cie, Paris
go back to reference Vanrietvelde F, Lemmerling M, Mespreuve M, Crevits L, De Reuck J, Kunnen M (2000) MRI of the brain in cerebrotendinous xanthomatosis (van Bogaert-Scherer-Epstein disease). Eur Radiol 10:576–578CrossRefPubMed Vanrietvelde F, Lemmerling M, Mespreuve M, Crevits L, De Reuck J, Kunnen M (2000) MRI of the brain in cerebrotendinous xanthomatosis (van Bogaert-Scherer-Epstein disease). Eur Radiol 10:576–578CrossRefPubMed
go back to reference Varadhan R, Weiss CO, Segal JB, Wu AW, Scharfstein D, Boyd C (2010) Evaluating health outcomes in the presence of competing risks: a review of statistical methods and clinical applications. Med Care 48:S96–105CrossRefPubMed Varadhan R, Weiss CO, Segal JB, Wu AW, Scharfstein D, Boyd C (2010) Evaluating health outcomes in the presence of competing risks: a review of statistical methods and clinical applications. Med Care 48:S96–105CrossRefPubMed
go back to reference Wakamatsu N, Hayashi M, Kawai H et al (1999) Mutations producing premature termination of translation and an amino acid substitution in the sterol 27-hydroxylase gene cause cerebrotendinous xanthomatosis associated with parkinsonism. J Neurol Neurosurg Psychiatry 67:195–198CrossRefPubMedPubMedCentral Wakamatsu N, Hayashi M, Kawai H et al (1999) Mutations producing premature termination of translation and an amino acid substitution in the sterol 27-hydroxylase gene cause cerebrotendinous xanthomatosis associated with parkinsonism. J Neurol Neurosurg Psychiatry 67:195–198CrossRefPubMedPubMedCentral
go back to reference Wang Z, Yuan Y, Zhang W, Zhang Y, Feng L (2007) Cerebrotendinous xanthomatosis with a compound heterozygote mutation and severe polyneuropathy. Neuropathology 27:62–66CrossRefPubMed Wang Z, Yuan Y, Zhang W, Zhang Y, Feng L (2007) Cerebrotendinous xanthomatosis with a compound heterozygote mutation and severe polyneuropathy. Neuropathology 27:62–66CrossRefPubMed
go back to reference Watts GF, Mitchell WD, Bending JJ, Reshef A, Leitersdorf E (1996) Cerebrotendinous xanthomatosis: a family study of sterol 27-hydroxylase mutations and pharmacotherapy. QJM 89:55–63CrossRefPubMed Watts GF, Mitchell WD, Bending JJ, Reshef A, Leitersdorf E (1996) Cerebrotendinous xanthomatosis: a family study of sterol 27-hydroxylase mutations and pharmacotherapy. QJM 89:55–63CrossRefPubMed
go back to reference Wevers RA, Cruysberg JR, Van Heijst AF et al (1992) Paediatric cerebrotendinous xanthomatosis. J Inherit Metab Dis 15:374–376CrossRefPubMed Wevers RA, Cruysberg JR, Van Heijst AF et al (1992) Paediatric cerebrotendinous xanthomatosis. J Inherit Metab Dis 15:374–376CrossRefPubMed
Metadata
Title
Natural history of neurological abnormalities in cerebrotendinous xanthomatosis
Authors
Janice C. Wong
Kailey Walsh
Douglas Hayden
Florian S. Eichler
Publication date
01-07-2018
Publisher
Springer Netherlands
Published in
Journal of Inherited Metabolic Disease / Issue 4/2018
Print ISSN: 0141-8955
Electronic ISSN: 1573-2665
DOI
https://doi.org/10.1007/s10545-018-0152-9

Other articles of this Issue 4/2018

Journal of Inherited Metabolic Disease 4/2018 Go to the issue

Obituary

In memoriam

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.